Skip to main content
S&P 5007,763.23-0.02%DOW51,810.75-0.46%NASDAQ27,212.99+0.34%BTC$86,455.00+0.53%ETH$2,746.60-0.21%GOLD$4,374.70-0.21%OIL$91.25-1.21%
Smart Investors Daily
GH

NASDAQ · GH

Guardant Health, Inc.

Healthcare · Medical - Diagnostics & Research

$173.87

Up+$2.82 (+1.62%)

Updated Sep 22, 2026, 5:17 PM

SID Score

6.8/10

Composite research score

Smart Money

54/100

Neutral

Market cap
12.58B
P/E ratio
-31.72
Dividend yield
0.00%
52-week range
$55.38 – $183.51
Volume
2.62M
Avg. volume
2.66M

Price performance

GH price history

1M range · 20 trading sessions · Daily adjusted prices

GH closed at $173.87 after 20 trading sessions, up 6.55% for the selected period.

Last close
$173.87
Period change
+6.55%
Period low
$157.38
Period high
$183.10
Daily close
View OHLC price history
GH OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 21, 2026$181.37$181.37$172.86$173.872.62M
Sep 18, 2026$183.00$183.50$175.62$179.383.08M
Sep 17, 2026$177.49$183.51$175.45$183.101.86M
Sep 16, 2026$175.00$179.39$173.82$174.901.52M
Sep 15, 2026$168.25$179.30$167.00$175.652.85M
Sep 14, 2026$156.55$168.15$155.775$167.841.49M
Sep 11, 2026$160.135$161.40$156.28$157.38695.95K
Sep 10, 2026$159.52$164.17$156.3171$159.031.06M
Sep 9, 2026$161.26$167.98$159.935$162.781.12M
Sep 8, 2026$166.11$166.69$160.25$160.982.04M
Sep 4, 2026$160.00$164.84$154.00$161.412.4M
Sep 3, 2026$164.09$166.42$159.59$161.041.19M
Sep 2, 2026$163.79$168.97$157.35$163.061.76M
Sep 1, 2026$158.50$165.63$156.32$164.412.44M
Aug 31, 2026$160.01$162.14$155.625$159.021.86M
Aug 28, 2026$166.35$169.60$160.23$161.501.82M
Aug 27, 2026$170.94$173.10$168.19$168.521.52M
Aug 26, 2026$164.71$173.1699$164.29$170.922.01M
Aug 25, 2026$164.535$167.90$161.22$164.921.19M
Aug 24, 2026$164.62$167.48$162.002$163.182.21M

Latest GH news

The latest Smart Investors Daily articles mentioning GH.

Stock researchCompany · Overview

GH research

Overview

Company profile and research snapshot.

Company profile

Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$93.00
Implied upside
—
Analysts
—
GH recent ratings
DateFirmRatingTarget
Sep 9, 2026UBSBuy—
Sep 8, 2026Rothschild & CoBuy—
Sep 2, 2026BTIGBuy—
Aug 4, 2026Piper SandlerOverweight—
Aug 4, 2026Stephens & Co.Overweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 18, 2026

Guardant Health (GH) Lands First FDA Cleared Breast Cancer Liquid Biopsy Role

Guardant Health (NasdaqGS:GH) received FDA approval for its Guardant360 CDx liquid biopsy as a companion diagnostic in advanced HR-positive, HER2-negative breast cancer. The decision makes Guardant360 CDx the first FDA approved liquid biopsy companion diagnostic for longitudinal ctDNA testing in breast cancer care. The approval is supported by clinical trial data where early detection of ESR1 mutations using Guardant360 CDx informed treatment changes for patients. The Guardant360 CDx breast...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By